



ASX Release

29 August 2017

ZELDA THERAPEUTICS LIMITED
ACN 103 782 378

Level 45
108 St Georges Terrace,
Perth Western Australia 6000
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com
Web: www.zeldatherapeutics.com

Contacts

Corporate

Mr Harry Karelis
Executive Chairman
+61 413 056 328
hkarelis@zeldatherapeutics.com

Investors

Dr Stewart Washer
Executive Director
+61 418 288 212
swasher@zeldatherapeutics.com

Directors

Mr Harry Karelis
Dr Stewart Washer
Ms Mara Gordon
Mr Jason Peterson

ASX Code:

ZLD

Ordinary Shares:

754,841,934

Options:

48,000,000

6,000,000 (\$0.04 - 6/2/2020 -
subject to vesting conditions)
2,000,000 (\$0.04 - 6/2/2020)
40,000,000 (\$0.03125-17/11/2021)

Priority Share Offer for CannPal Animal Therapeutics IPO Shares

The Board of **Zelda Therapeutics Ltd (ASX: ZLD, Zelda or the Company)** is pleased to announce that its shareholders are invited to participate as a priority applicant in the prospectus capital raising of CannPal Animal Therapeutics Limited (CannPal) lodged with the ASIC.

CannPal is a pet pharmaceutical company and is in the process of listing on the Australian Securities Exchange (ASX) by way of an initial public offering ("IPO"). CannPal has issued a prospectus dated 28 August 2017 (Prospectus) to raise \$6 million to progress CannPal's clinical research and development plans for its pharmaceutical and nutraceutical products. The Prospectus can be found on CannPal's website (www.cannpal.com).

As announced on 23 March 2017, ZLD has entered into a strategic partnership with CannPal to promote and encourage collaborative activity and exploit opportunities of mutual interest in both the human and animal pharmaceutical markets through the sharing of research data compiled by each of the parties.

Under the Prospectus, 5,000,000 fully paid ordinary shares (Shares) at \$0.20 per Share have been allocated and made available to those ZLD shareholders registered on 1 September 2017 holding a minimum of 25,000 ZLD shares (Eligible ZLD Shareholders) collectively on a priority application basis. The minimum subscription is 10,000 shares (\$2,000) as set out in the CannPal Prospectus (Priority Offer). Allocation of the Shares to the Eligible ZLD Shareholders pursuant to the Priority Offer will be subject to the allocation policy set out in Section 5.5 of the Prospectus. Any Eligible ZLD Shareholder looking to participate in the Priority Offer should read the Prospectus in its entirety and make their own investment decision.

Tim Slate
Company Secretary

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics ("Zelda") is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising:

- A human clinical trial programme focused on insomnia, autism and eczema with activities in Australia and Chile.
- A pre-clinical research programme examining the effect of cannabinoids in breast, brain and pancreatic cancer. It has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer.

The Company has secured certain rights to medicinal cannabis based formulations and treatment protocols developed over many years by a California-based group (Aunt Zelda's) that has a very high profile within the USA and a growing international profile.